abbvie stock forecast 2030 abbvie stock forecast 2030

Receive ABBV Stock News and Ratings via Email. That was below AbbVie stock analysts' view for $14.16. For the next eight years, the forecast is for Free Cash Flow to grow by . ET comments Please log in to your account or sign up in order to add this asset to your watchlist. Migraine therapy Ubrelvy is a future blockbuster, Gonzalez believes, as is Qulipta, in the same indication. In my model I have then reduced revenues by 20% between 2024 - 2026, and then by 10% per annum between 2027 - 2030. Finally I can present a target price for AbbVie stock in 2023 using DCF / EBITDA analysis. All rights reserved. Payout ratios above 75% are not desirable because they may not be sustainable. As a result I have dropped Imbruvica revenues to just over $3.5bn in 2022 and modelled for a CAGR growth of just 1.5% between then and 2030. Negative dynamics for AbbVie shares will prevail with possible volatility of 1.976%. Ltd., AbbVie Pty Ltd, AbbVie Purchasing LLC, AbbVie Real Estate Management GmbH, AbbVie Research B.V., AbbVie Resources Inc., AbbVie Resources International Inc., AbbVie Respiratory LLC, AbbVie S. de R.L., AbbVie S.A., AbbVie S.A., AbbVie S.A.S., AbbVie S.R.L., AbbVie S.r.l., AbbVie S. r.l., AbbVie SA, AbbVie SAS, AbbVie SIA, AbbVie Sarl, AbbVie Sdn. We now expect global sales for Skyrizi to reach more than $10 billion in 2025, an increase of $2.5 billion versus our previous guidance, reflecting higher performance across basically all of the indications. It should be noted that the strength of the competition AbbVie faces from other Pharma's desperate to claim a larger share of the immunology markets after Humira's LOE is fierce - Eli Lilly's (LLY) Olumiant, Pfizer's (PFE) Zeljanz, Amgen's Otezla, Bristol Myers Squibb's (BMY) Zeposia, Johnson & Johnson's (JNJ) Tremfya, Novartis' (NVS) Cosentyx and Regeneron (REGN) / Sanofi's (SNY) Dupixent to name a few. My EPS figure increases slightly between 2022 and 2023, whilst AbbVie has suggested it will be down slightly before beginning to accelerate towards the end of the decade, as revenues correspondingly begin to climb sharply once the worst of the Humira LOE is over. These products are not suitable for everyone and you should therefore consider your objectives, financial situation, needs and experience with these products before investing in them. In the last two years, Aurora Cannabis's Revenue has fallen from C$245.54M to C$245.25M - a 0.12% decrease. Perhaps this is an example of how ruthless management can be when encountering falling sales, and a warning that not all company divisions are guaranteed to thrive. Morningstar: 2019 Morningstar, Inc. All Rights Reserved. The pharma industry witnessed solid growth amid the pandemic. Sales are expected to recover in H2'22, however, and forecast year-on-year growth. At their peak, according to a slide from AbbVie's presentation at the JPMorgan (JPM), these 2 drugs are expected to generate more revenues than Humira at its peak. Their ABBV share price forecasts range from $140.00 to $200.00. There are still very few approved therapies, although that could change with Crispr Therapeutics (CRSP) / Vertex (VRTX) Sickle Cell Disease therapy leading the charge in 2023. Based on earnings estimates, ABBV will have a dividend payout ratio of 54.11% next year. The shining star in the aesthetics business is Botox, which increased sales by 45% year over year to $477 million in the first quarter of 2021. On the negative side of things, we can see that AbbVie is no longer breaking out sales within its Women's Health division, with revenues lumped into the "all other section, presumably. I am modelling for AbbVie to grow revenues at a compound annual growth rate of ~5% between now and 2030 with growth accelerating in the latter half of the decade. I also considered the long-term outlook for a company that is still only 10 years old and is about to feel the impact of a loss of patent protection for its mega-blockbuster auto-immune drug Humira, which made $20.7bn of sales for the company in FY21, representing 37% of total revenues generated. Enjoy your holiday weekend and catch up on our most read stories this week. The fact that my own forecasts are less ambitious than management's reflects the fact I have not introduced new products into my forecasts, and it will be interesting to see how management performs on that front as AbbVie has not really had to have a string pipeline while Humira has delivered such dominance in the auto-immune markets. First of all, as shown in the table above I forecast product sales out to 2030. Wallet Investor suggested that the price could hit $300.386 in June 2027. Factset: FactSet Research Systems Inc.2019. Johnson & Johnson is rushing toward a patent cliff but a new shelf offering registration suggests itis gearing up for acquisitions. However, there are some general principles that can be followed in order to improve the accuracy of stock price predictions. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Aesthetics was propped up by growing sales of Botox - up 12% year-on-year to $678m, but let down by sales of Juvederm, which management put down to lockdown regulations in China, and the "suspension" of operations in Russia. AbbVie will have to drop its price point to compete with the generics however, plus there is the 10% of the market it is not covered for, so an overall 20% decline in revenues in 2023 seems accurate. AbbVie Aesthetics / Neurology revenues forecasts to 2030 (my table and assumptions) . AbbVie Stock Forecast 2022 - 2025 - 2030 | StockForecast.com GB Receive regular, detailed analysis focused on biotech and healthcare stocks. As per management's guidance, I am modelling for $5.7bn of revenues in 2023, with growth beginning to accelerate substantially from 2025 / 26 onwards. (AbbVie JPM Healthcare conference presentation). The company's average rating score is 2.44, and is based on 7 buy ratings, 9 hold ratings, and no sell ratings. AbbVie updated its FY 2024 earnings guidance on Friday, February, 10th. Finally I can present a target price for AbbVie stock in 2023 using DCF / EBITDA analysis. It revealed that patients with moderate to severe Crohns disease receiving Abbvies Rinvoq achieved steroid-free clinical remission in significantly higher numbers than patients receiving a placebo. In my modeling table above, I estimate Humira sales will decline by 25% between 2022 and 2023, to ~$16bn, although some of that lost revenue will be gobbled up by Skyrizi/Rinvoq. Management are very optimistic on Vraylar, with Gonzalez describing it as "now the only antipsychotic that is a dopamine and serotonin partial agonist approved for the treatment of the most common forms of depression, Bipolar 1 and MDD" and targeting >$5bn peak sales. z o.o., AbbVie Productos Farmacuticos Limitada, AbbVie Products LLC, AbbVie Promoo L.da, AbbVie Pte. Psoriatic arthritis is also adding significantly to Skyrizi's momentum, where we are now approved in 54 countries. As of 2022, AbbVie employed more than 50,000 people globally with 21,000 in STEM-related positions. How often does AbbVie pay dividends? The company has been increasing its dividend for 51 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. According to 23 major analysts, AbbVie's Fair Value will fall by 5.43% in the next year, reaching $122.98. Aurora Cannabis Revenue Forecast for 2023 - 2025 - 2030. As with debt, if approval and revenue targets aren't met, it can quickly result in a loss of faith in the company. AbbVie has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Both Leqembi and Donanemab are potential $5bn - $10bn selling assets, but both drugs still have safety questions to answer and not certain to be made eligible for reimbursement. Shareholders of record on Friday, April 14th will be given a dividend of $1.48 per share on Monday, May 15th. In February, a Phase 3 induction study saw positive top-line results. This included an unfavourable impact of $0.08 a share related to acquired in-process research and development (IPR&D) and milestones expenses incurred during the March quarter. Botox accounts for the bulk of the companys Aesthetics portfolio revenue and about 4% of the net as of 2022. Although Wallet Investor did not provide targets for 2030, its longer-term Abbvie stock prediction expected the price to hit $300.386 in June 2027. The average analyst rating for AbbVie stock from 34 stock analysts is "Buy". Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. Stock Price Forecast The 21 analysts offering 12-month price forecasts for Abbvie Inc have a median target of 165.00, with a high estimate of 200.00 and a low estimate of 135.00. As I have mentioned in previous notes, however, the gains owe more to price hikes than sales volumes, and come 2023 and the LOE, even AbbVie admits the blow to revenues will be substantial. Only you can design whether Abbvie stock is the right investment for you. It . The firm's revenue for the quarter was up 1.6% compared to the same quarter last year. Drug development has not traditionally been one of AbbVie's strengths - it has not had to be - but we ought to see the positive results of heavy investment into the oncology pipeline over the next 5-7 years, and by 2030, I believe this division could account for >17% of AbbVie's total revenues. Snowflake Reports Weak Guidance: Is the Growth Snowflake Melting? Remember that past performance is not a guarantee of future results and you should never invest more money than you can afford to lose. I look forward to seeing if Epcoritamab is approved this year, and although there is not a lot else in the near-term pipeline at this time, I also look forward to seeing how other projects may progress, e.g., opportunities in Parkinson's Disease, Alzheimer's and Cystic Fibrosis. My calculation is that Humira revenues in 2023 will be 80% of the 2022 figure, or $16.7bn. The company's lead asset - all-time best selling immunology drug Humira - finally loses patent protection this year and sales will enter a period of terminal decline. The S&P 500 (US500) lost 9.1%, the Dow Jones (US30) slid 9.7%, and the Nasdaq Composite fell 23% during the same period. The material provided on this website is for information purposes only and should not be understood as an investment advice. And we remain confident in our ability to achieve total sales of more than $9 billion by 2029. Their ABBV share price forecasts range from $140.00 to $200.00. The median. ABBV-916 is targeting Alzheimer's and it is an anti-amyloid antibody, with a similar mechanism of action ("MoA") to recently approved Leqembi, developed by Biogen (BIIB) / Eisai, and likely soon-to-be approved Donanemab, developed by Eli Lilly. The consensus among Wall Street research analysts is that investors should "hold" ABBV shares. Richard A. Gonzalez has an approval rating of 88% among the company's employees. Skyrizi has also been approved to treat Crohn's Disease, an added bonus and another multi-billion dollar market. Although the company has admitted that 2023 earnings will likely be down in 2022 - guidance for last year is for earnings per share ("EPS') of $13.84 - $13.88 on an adjusted diluted basis, versus $12.7 in 2021 - Gonzalez and his team were making some bold promises to investors at this year's JP Morgan Healthcare conference. I have no business relationship with any company whose stock is mentioned in this article. Top institutional shareholders include Geode Capital Management LLC (1.91%), Morgan Stanley (1.79%), Moneta Group Investment Advisors LLC (1.65%), Price T Rowe Associates Inc. MD (1.15%), Norges Bank (1.06%) and Legal & General Group Plc (0.66%). I write about Biotech, Pharma and Healthcare stocks and share investment tips. With AbbVie's revenues accelerating past $80bn in 2030 (by my calculation), and cash flow generated in that year being >$25bn, after applying discount factors for each year I reach a price target of $176 - the average of DCF - $162 per share - and EBITDA - $189 per share - calculations. Sign in to your free account to enjoy all that MarketBeat has to offer. Venclexta continues to pick up momentum with sales up 16% to >$500m in Q2'22, and I forecast the drug to exceed $3.2bn in revenues by the end of the decade. I have speculatively assigned peak sales of $2bn, although it should be noted that success here is far from guaranteed, although if AbbVie did succeed with ABBV916 sales could be 2 or 3x higher than my forecast. Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter. AbbVie Stock Forecast 03-06-2023. Between September 2021 and April 2022, AbbVie stock went on a sensational bull run, gaining 62% and hitting an all-time peak of $174. The company is a member of the Fortune 100 and one of the Fortune 100s Best Companies To Work For. Join the 500.000+ traders worldwide that chose to trade with Capital.com, Also you can contact us: The companys full-year adjusted diluted EPS guidance excluded any impact from acquired IPR&D and milestones that may be incurred beyond the first quarter of the year, as both cannot be reliably forecasted. The risks associated with aesthetics are that the industry can be severely buffeted by economic headwinds, as these products are more consumer focused and are often considered an unnecessary expenditure in times of hardship. After 2022 Humira's row is shaded yellow to signify patent expiry. The average ABBVIE INC stock forecast 2023 represents a 1.86% increase from the last price of $153.729995727539. That is interesting to me as I think it suggests management will need to commercialize more assets if it wants to hit that target. Duodopa is approved for Parkinson's Disease but Gonzalez believes that the subcutaneous non-surgical delivery system of candidate ABBV951 can "significantly expand the patient population currently addressed by Duopa", and sees the drug as yet another future blockbuster. To date, the company had invested more than $50 billion into research through more than 250 partnerships. Retail sales were up but so was inflation which meant more volatility for stocks. 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. Their combined revenues are expected to reach $7.5bn in 2022, and Gonzalez told the audience at JPM that: Skyrizi and Rinvoq are now on pace to deliver more than $17.5 billion in combined sales, risk adjusted sales in 2025, well above our previous expectations. When looking for ABBV stock forecasts, it's important to bear in mind that analysts' forecasts can be wrong. 8.05% That is a significant difference because at a forward P/E of 10x AbbVie stock looks like a solid buy opportunity, but at a P/E of 20x, when we consider the risk/challenge of Humira's LOE, prospective investors may prefer to maintain a watching brief as opposed to opening a position. Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. Only 0.08% of the stock of AbbVie is held by insiders. AbbVie projected sales - immunology (my forecasts and assumptions). Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. Finally, AbbVie was able to raise its financial . RHHBY vs. ABBV: Which Stock Is the Better Value Option? What is Richard A. Gonzalez's approval rating as AbbVie's CEO? To see all exchange delays and terms of use please see Barchart's disclaimer. This suggests a possible upside of 3.2% from the stock's current price. The 21 analysts offering 12-month price forecasts for Abbvie Inc have a median target of 165.00, with a high estimate of 200.00 and a low estimate of 135.00. Most stock quote data provided by BATS. Let's begin our analysis with the immunology division. Discovery Company. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. PEG Ratios above 1 indicate that a company could be overvalued. Our momentum combined with ramping contributions from new products and new indications will drive accelerating revenue and EPS growth through the rest of the year., ABBV has done very well to add to its impressive gains from the past couple of years. The CEO, speaking at a fireside chat during the conference, commented: we remain well-positioned to absorb the impact from the Humira LOE and quickly return to strong growth starting in 2025. Since its 2013 separation from Abbott Laboratories (ABT 1.78%), AbbVie's stock has grown more than 160%. In the last two years, GSK's Free Cash Flow has grown by 0.37%, rising from 6.76B to 6.78B. This rating has held steady since February, when it was unchanged from a Buy rating.Move your mouse over pastmonths for detail. I wrote this article myself, and it expresses my own opinions. In 2022, Humira revenues will likely reach $21bn, which will see the drug overtake cholesterol-lowering Lipitor as the best-selling drug of all-time. The companys original winner, Humira, is still the number one revenue source but the portfolio has been greatly expanded. Capital Com Australia Pty Ltd (ABN 47 625 601 489) is a company registered in Australia and regulated by the Australian Securities and Investments Commission (ASIC) under AFSL 513393. Investors do not seem to be taking the bait, however, as AbbVie's share price has slipped by >7% across the past month, and >5% across the past 5 days. I'm on twitter @edmundingham. Analysts have tipped the drug to achieve peak sales of $2.75bn, and although the emergence of CAR-T therapies and some concerns around safety - notably cases of cytokine release syndrome ("CRS') - persist, this revenue figure is achievable in my view. Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), AT&T (T), Bristol-Myers Squibb (BMY), Wheaton Precious Metals (WPM), Rogers Communications (RCI) and Open Text (OTEX). (JPM Healthcare conference presentation), Skyrizi's performance has been particularly eye-catching. I am not receiving compensation for it (other than from Seeking Alpha). Your current $100 investment may be up to $188.28 in 2028. According to 34 stock analysts, the average 12-month stock price forecast for AbbVie stock is $166.14, which predicts an increase of 7.62%. AbbVie income statement forecast (My table and assumptions). Get daily stock ideas from top-performing Wall Street analysts. AT&T Inc. (T) stock forecast and price target Find the latest AT&T Inc. T analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. 2022 Cable News Network. AbbVie (NYSE:ABBV) has a market capitalization of $276.13 billion and generates $58.05 billion in revenue each year. call (03) 8658 0539 support.au@capital.com. It is a Top 50 Company regarding diversification and a member of the Dow Jones Sustainability World Index and the S&P ESG Index. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Find the latest AbbVie Inc. (ABBV) stock quote, history, news and other vital information to help you with your stock trading and investing. In terms of market cap, it ranks third behind Pfizer ( PFE) and Novo Nordisk ( NVO ). The dividend payout ratio of AbbVie is 89.56%. View institutional ownership trends. Price target. Rinvoq's progress has been a little more circumspect, but almost as impressive. One of the few pain points AbbVie experienced during a year of portfolio wide growth in 2022 was the decline in the revenue contribution from Imbruvica, approved to treat various types of lymphoma. That is substantially higher than the 12% CAGR achieved between 2018 - 2022, although that period includes the additional revenues from Allergan. Revance Therapeutics gapped up 54.34% on January 9, and built upon those gains in February. The company officially IPOd on January 2, 2013; contrary to criticisms, the move was solely to protect the parent company from expiring patents. CFDs are complex leveraged instruments and come with a high risk of losing money. Other approved ADC's targeting the c-Met protein, a validated target in NSCLC, include Novartis Tabrecta, which has been pegged for peak sales of ~$1.5bn, which seems a realistic target for Teliso given how large the lung cancer market is - the largest of all oncology markets. There is no mention of Women's Health in the Q2'22 earnings call or in the 10-Q submission to the SEC, or any of the drugs within it, yet the divisions have not (to the best of my knowledge) been sold, despite rumors it was put up for sale at ~$5bn. Abbvie Stock Forecast 2023 In the Biopharmaceutical Industry, Abbvie has been able to create a leadership position in the market in each business segment with different brand names in different business categories like Immunology, Hematologic Oncology, Neuroscience, Aesthetics, and Eye Care. PMeds are designed not only to target the specific causes of diseases, often at the genetic level, but the patients that are most likely to benefit from them. It now expects full-year profit in the range of $13.92-$14.12 a share. Earnings for AbbVie are expected to decrease by -0.55% in the coming year, from $11.00 to $10.94 per share. It had an upside potential of 4.76%, based on the closing price of $152.49 on 29 June. The P/E ratio of AbbVie is 23.61, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 126.03. AbbVie discounted cash flow analysis. It is in business to discover, develop, manufacture and market pharmaceuticals globally but in a way that best serves the needs of patients and the global community. The lowest target is $136.35 and the highest is $210. outlook for a company that is still only 10 years old and is about to feel the impact of a loss of patent protection for its mega-blockbuster auto-immune drug Humira, which made $20.7bn of sales for the company in FY21, representing 37% of total revenues generated. Armed with management's detailed guidance and commentary on sales performance of key assets and new product launches, however, I have completed sales projections for AbbVie to 2030, which I will share in this post, highlighting areas of strength and potential weaknesses. I have no business relationship with any company whose stock is mentioned in this article. How do I arrive at my share price target? Both of these assets appear to be doing the job they were intended for - protecting AbbVie's dominance in various auto-immune markets - and now represent ~13% of AbbVie's total revenue generation. According to analysts' consensus price target of $161.12, AbbVie has a forecasted upside of 3.2% from its current price of $156.06. As such, forecasting stock prices is more of an art than a science. AbbVie's success - as its shareholders will doubtless be aware - stems from the runaway success of its immunology drug Humira, which is indicated for a range of autoimmune conditions, including Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, Crohn's Disease, Ulcerative Colitis, Hidradenitis Suppurativa and Ankylosing spondylitis. Read the conference call transcript. Finally, eye-care - another division inherited from Allergan - has been performing well for AbbVie although I am not expecting particularly strong growth from the current product portfolio. Ever since its split from Abbott Laboratories (ABT) in 2012 AbbVie (NYSE:ABBV) has delivered strong returns for investors - its stock price having risen overall from $30, to $149 per share at the time of writing - trading down slightly from its all-time high of >$160 achieved in early December last year. Find me at my marketplace channel, Haggerston BioHealth - model portfolio + 4 exclusive stock tips every week. Is this happening to you frequently? AbbVie's post-Humira LOE plans are not riskless, and its targets are ambitious, but nevertheless I see no harm in picking up shares in the Pharma at the current price, accepting a generous 4% dividend, and likely benefitting from share repurchases and a steadily growing share price until 2030. The analysts 12-month consensus ABBV stock price target was $159.75. The official website for the company is www.abbvie.com. AbbVie saw a increase in short interest in February. Forecast target price for 03-06-2023: $ 152.58. ABBV closed at $152.49 on 29 June, which was above its 200-day moving average (MA) of 136.42, indicating a bullish signal for the stocks price movement ahead, according to data from TradingView.